Rezolute (NASDAQ:RZLT – Get Free Report) and Akero Therapeutics (NASDAQ:AKRO – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Volatility & Risk
Rezolute has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Rezolute and Akero Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rezolute | 0 | 0 | 7 | 1 | 3.13 |
| Akero Therapeutics | 0 | 0 | 9 | 0 | 3.00 |
Valuation and Earnings
This table compares Rezolute and Akero Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rezolute | N/A | N/A | -$68.46 million | ($1.22) | -2.39 |
| Akero Therapeutics | N/A | N/A | -$151.76 million | ($3.75) | -11.62 |
Akero Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Rezolute and Akero Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rezolute | N/A | -70.27% | -62.41% |
| Akero Therapeutics | N/A | -32.46% | -29.83% |
Insider & Institutional Ownership
83.0% of Rezolute shares are held by institutional investors. 18.4% of Rezolute shares are held by company insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Rezolute beats Akero Therapeutics on 9 of the 12 factors compared between the two stocks.
About Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
About Akero Therapeutics
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
